4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | 284.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 284.41% |
| Mar 31, 2026 | 115.63% |
| Dec 31, 2025 | -1,925.29% |
| Sep 30, 2025 | -34.88% |
| Jun 30, 2025 | 81.16% |
| Mar 31, 2025 | 112.14% |
| Dec 31, 2024 | 205.64% |
| Sep 30, 2024 | -8.94% |
| Jun 30, 2024 | -249.20% |
| Mar 31, 2024 | -710.38% |
| Dec 31, 2023 | 81.32% |
| Sep 30, 2023 | 95.05% |
| Jun 30, 2023 | -14.23% |
| Mar 31, 2023 | 179.71% |
| Dec 31, 2022 | -10.80% |
| Sep 30, 2022 | 111.06% |
| Jun 30, 2022 | 7,897.56% |
| Mar 31, 2022 | -8,328.35% |
| Dec 31, 2021 | -6,256.50% |
| Sep 30, 2021 | -39,930.95% |